PMID- 24641422
OWN - NLM
STAT- MEDLINE
DCOM- 20141118
LR  - 20190606
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 15
IP  - 4
DP  - 2014
TI  - Low level of TERC gene amplification between chronic myeloid leukaemia patients 
      resistant and respond to imatinib mesylate treatment.
PG  - 1863-9
AB  - The amplification of telomerase component (TERC) gene could play an important 
      role in generation and treatment of haematological malignancies. This present 
      study was aimed to investigate copy number amplification status of TERC gene in 
      chronic myeloid leukaemia (CML) patients who were being treated with imatinib 
      mesylate (IM). Genomic DNA was extracted from peripheral blood of CML-IM 
      Resistant (n=63), CML-IM Respond (n=63) and healthy individuals (n=30). TERC gene 
      copy number predicted (CNP) and copy number calculated (CNC) were determined 
      based on Taqman(R) Copy Number Assay. Fluorescence in situ hybridization (FISH) 
      analysis was performed to confirm the normal signal pattern in C4 (calibrator) 
      for TERC gene. Nine of CML patients showed TERC gene amplification (CNP=3), 
      others had 2 CNP. A total of 17 CML patients expressed CNC>2.31 and the rest had 
      2.31>CNC>1.5. TERC gene CNP value in healthy individuals was 2 and their CNC 
      value showed in range 1.59-2.31. The average CNC TERC gene copy number was 2.07, 
      1.99 and 1.94 in CML- IM Resistant patients, CML-IM Respond and healthy groups, 
      respectively. No significant difference of TERC gene amplification observed 
      between CML-IM Resistant and CML-IM Respond patients. Low levels of TERC gene 
      amplification might not have a huge impact in haematological disorders especially 
      in terms of resistance towards IM treatment.
FAU - Mohamad Ashari, Zaidatul Shakila
AU  - Mohamad Ashari ZS
AD  - Human Genome Center, School of Medical Sciences, Health Campus, Universiti Sains 
      Malaysia, Kubang Kerian, Kelantan, Malaysia E-mail : ssarina@kck.usm.my.
FAU - Sulong, Sarina
AU  - Sulong S
FAU - Hassan, Rosline
AU  - Hassan R
FAU - Husin, Azlan
AU  - Husin A
FAU - Sim, Goh Ai
AU  - Sim GA
FAU - Abdul Wahid, S Fadilah
AU  - Abdul Wahid SF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (Benzamides)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 0 (telomerase RNA)
RN  - 63231-63-0 (RNA)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - EC 2.7.7.49 (Telomerase)
SB  - IM
MH  - Benzamides/*therapeutic use
MH  - Cross-Sectional Studies
MH  - DNA Copy Number Variations
MH  - Drug Resistance, Neoplasm/genetics
MH  - Gene Amplification/*genetics
MH  - Gene Dosage/*genetics
MH  - Humans
MH  - Imatinib Mesylate
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy/*genetics
MH  - Piperazines/*therapeutic use
MH  - Pyrimidines/*therapeutic use
MH  - RNA/*genetics
MH  - Telomerase/*genetics
EDAT- 2014/03/20 06:00
MHDA- 2014/11/19 06:00
CRDT- 2014/03/20 06:00
PHST- 2014/03/20 06:00 [entrez]
PHST- 2014/03/20 06:00 [pubmed]
PHST- 2014/11/19 06:00 [medline]
AID - 10.7314/apjcp.2014.15.4.1863 [doi]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2014;15(4):1863-9. doi: 10.7314/apjcp.2014.15.4.1863.